MDxHealth, Inc. Holds Capital Markets Day In New York City

Key Opinion Leaders Highlight MDxHealth’s Commercial Portfolio

IRVINE, CA, and HERSTAL, BELGIUM – June 14, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced that a replay of its Capital Markets Day presentation, held earlier today in New York City, is currently available. During the event, management provided an overview of company operations, including the commercial status of its ConfirmMDx® and SelectMDx™ tests for prostate cancer and an R&D review that highlighted AssureMDx™ for bladder cancer. No new information was reported.

Guest speakers included E. David Crawford, MD, Head of Urologic Oncology at the University of Colorado Denver (UCD), and Neal Shore, MD, Director CPI, Carolina Urologic Research Center, Myrtle Beach, South Carolina.

An event webcast replay is now available at the MDxHealth investor website at www.mdxhealth.com/investors.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com

Consilium Strategic Communications
Amber Fennell, Chris Welsh & Hendrik Thys
UK: +44 20 3709 5701
mdxhealth@consilium-comms.com

Rx Communications Group, LLC
Melody Carey, Steve Silver
US: 917-322-2571/917-322-2569
mdxhealth@rxir.com

Back to news